Alvotech Feed

	Est. tid*
2024-11-13	-	Kvartalsrapport 2024-Q3
2024-08-16	-	Kvartalsrapport 2024-Q2
2024-05-17	-	Kvartalsrapport 2024-Q1
2023-11-14	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-06-06	-	Årsstämma
2023-05-19	-	Kvartalsrapport 2023-Q1

Land	Island
Lista	Large Cap Iceland
Sektor	Hälsovård
Industri	Medicinteknik

2025-03-27 09:30:00 Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer 1450,00 ISK | -6,45%

2025-03-26 23:36:27 Alvotech birtir metuppgjör fyrir árið 2024, sem sýnir mikla tekjuaukningu og kynnir nýjar áherslur og áfanga í rekstri félagsins 1550,00 ISK | +0,16%

2025-03-26 23:36:27 Alvotech Reports Record Results for 2024 and Provides Business Update 1550,00 ISK | +0,16%

2025-03-26 23:34:45 Alvotech Reports Record Results for 2024 and Provides Business Update 1550,00 ISK | +0,16%

2025-03-26 09:30:00 Lyfjastofnun Bretlands samþykkir að taka til umsagnar umsókn um markaðsleyfi fyrir fyrirhugaða hliðstæðu við Xolair 1550,00 ISK | +0,16%

2025-03-26 09:30:00 UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) 1550,00 ISK | +0,16%

2025-03-20 08:00:00 Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production 1540,00 ISK | +3,01%

2025-03-20 08:00:00 Alvotech kaupir þróunarstarfsemi líftæknifyrirtækisins Xbrane í Svíþjóð 1540,00 ISK | +3,01%

2025-03-20 08:00:00 Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production 1540,00 ISK | +3,01%

2025-03-18 13:30:00 Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) samþykkir að taka til afgreiðslu umsókn um markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva 1515,00 ISK | +0,33%

2025-03-18 13:30:00 Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® 1515,00 ISK | +0,33%

2025-03-07 15:00:00 Alvotech fundar með fjárfestum á alþjóða heilbrigðisráðstefnu Barclays fjárfestingabankans í Miami og situr fyrir svörum 1520,00 ISK | +1,00%

2025-03-07 15:00:00 Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida 1520,00 ISK | +1,00%

2025-02-24 14:00:00 Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET 1675,00 ISK | -2,33%

2025-02-24 14:00:00 Alvotech heldur kynningarfund fyrir fjárfesta 27. mars 2025, eftir birtingu uppgjörs fyrir árið 2024 og fjórða ársfjórðung 1675,00 ISK | -2,33%

2025-02-21 12:00:00 Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. 1715,00 ISK | +3,63%

2025-02-21 12:00:00 Alvotech og Teva tilkynna að sala er hafin í Bandaríkjunum á Selarsdi (ustekinumab-aekn), hliðstæðu við líftæknilyfið Stelara 1715,00 ISK | +3,63%

2025-02-21 12:00:00 Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. 1715,00 ISK | +3,63%

2025-02-18 12:00:00 Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) 1785,00 ISK | -0,56%

2025-02-18 12:00:00 Alvotech og Teva tilkynna að umsókn um markaðsleyfi í Bandaríkjunum fyrir AVT06, fyrirhugaða hliðstæðu við augnlyfið Eylea, hafi verið tekin til umsagnar 1785,00 ISK | -0,56%

2025-02-18 12:00:00 Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) 1785,00 ISK | -0,56%

2025-01-27 12:00:00 Alvotech og Teva tilkynna að FDA hefur tekið til umsagnar umsókn um markaðsleyfi í Bandaríkjunum fyrir AVT05, fyrirhugaða hliðstæðu við Simponi og Simponi Aria (golimumab) 1795,00 ISK | -0,28%

2025-01-27 12:00:00 Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) 1795,00 ISK | -0,28%

2025-01-03 19:00:00 Alvotech birtir fjárhagsdagatal fyrir árið 2025 1840,00 ISK | -0,54%

2024-12-23 10:00:00 Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 1740,00 ISK | +5,78%

2024-12-23 10:00:00 Hlutabréf Alvotech tekin inn í Líftæknivístölu Nasdaq 1740,00 ISK | +5,78%

2024-12-23 10:00:00 Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 1740,00 ISK | +5,78%

2024-11-13 22:05:00 Alvotech Reports Financial Results for the First Nine Months of 2024 1690,00 ISK | +0,60%

2024-11-13 22:05:00 Alvotech birtir fjárhagsuppgjör fyrir fyrstu níu mánuði ársins 2024 1690,00 ISK | +0,60%

2024-11-13 22:05:00 Alvotech Reports Financial Results for the First Nine Months of 2024 1690,00 ISK | +0,60%

2024-11-07 14:00:00 Alvotech fundar með fjárfestum á heilbrigðisráðstefnum Citi og Evercore fjárfestingabankanna dagana 4. og 5. desember 2024 1765,00 ISK | -1,67%

2024-11-07 14:00:00 Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024 1765,00 ISK | -1,67%

2024-11-04 13:00:00 Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT05, fyrirhugaða líftæknilyfjahliðstæðu við Simponi (golimumab) 1790,00 ISK | -1,65%

2024-11-04 13:00:00 European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) 1790,00 ISK | -1,65%

2024-10-30 13:30:00 Alvotech mun birta uppgjör fyrstu níu mánaða ársins miðvikudaginn 13. nóvember nk. og streyma uppgjörsfundi fimmtudaginn 14. nóvember nk. kl. 13:00 að íslenskum tíma 1730,00 ISK | -3,89%

2024-10-30 13:30:00 Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET 1730,00 ISK | -3,89%

2024-10-25 14:00:00 Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 1800,00 ISK | +0,28%

2024-10-25 14:00:00 Alvotech fundar með fjárfestum og heldur kynningu á heilbrigðisráðstefnu Jefferies í London 19.-20. nóvember 2024 1800,00 ISK | +0,28%

2024-10-25 14:00:00 Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 1800,00 ISK | +0,28%

2024-10-22 13:00:00 Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) 1710,00 ISK | +1,18%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Kalender

Beskrivning

Alvotech

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden